CD70 Antibody: Applications, Specificity & Research Use

CD70 Antibody is a research-grade immunological tool designed to detect and characterize CD70 (CD27 ligand), a TNF superfamily member critically involved in lymphocyte activation, memory T-cell generation, and tumor immune evasion.

Target Antigen

CD70 (CD27 Ligand, TNFSF7)

Product SKU

Ab348619

Protein Family

TNF Superfamily (TNFSF7)

Key Biological Role

Co-stimulatory ligand for CD27; regulates T-cell and NK-cell activation and survival

Research Areas

Tumor immunology, lymphocyte biology, immune checkpoint research

Supplier

Aladdin Scientific (catalog: Ab348619)

CD70 Target Biology and Significance

CD70, encoded by the TNFSF7 gene, is a type II transmembrane glycoprotein and a member of the tumor necrosis factor (TNF) superfamily. It serves as the sole known ligand for CD27, a co-stimulatory receptor expressed predominantly on naive and memory T cells, B cells, and natural killer (NK) cells. The CD70–CD27 signaling axis plays a pivotal role in the clonal expansion of antigen-specific T cells, the differentiation of B cells into plasma cells, and the long-term maintenance of immune memory.

Under normal physiological conditions, CD70 expression is tightly regulated and transient, appearing briefly on activated dendritic cells, T cells, and B cells. However, aberrant and constitutive CD70 expression has been documented across a broad spectrum of malignancies—including renal cell carcinoma (RCC), diffuse large B-cell lymphoma (DLBCL), glioblastoma, and certain solid tumors—making CD70 a compelling biomarker and therapeutic target in oncology research.

Understanding CD70 expression patterns, protein interactions, and downstream signaling is therefore central to studies in tumor immunology, adoptive cell therapy optimization, and immune checkpoint biology.

Validated Applications of CD70 Antibody (Ab348619)

The CD70 Antibody (Ab348619) from Aladdin Scientific is intended for use as a research reagent in the detection and study of CD70 protein. Antibodies targeting CD70 are commonly validated for the following laboratory applications:

• Flow Cytometry (FC/FACS): Detection of cell-surface CD70 expression on activated immune cells or tumor cell lines, enabling quantitative analysis of CD70-positive populations.
• Immunohistochemistry (IHC): Localization of CD70 protein in formalin-fixed, paraffin-embedded (FFPE) tissue sections, commonly used to assess expression in tumor biopsies and lymphoid tissues.
• Immunofluorescence (IF): Visualization of CD70 distribution in fixed cells or tissue sections using fluorescence microscopy.
• Western Blot (WB): Detection of denatured CD70 protein in cell or tissue lysates to confirm target expression and approximate molecular weight.
• Immunoprecipitation (IP): Enrichment of CD70 protein complexes from lysates for downstream interaction studies.

Researchers should consult the specific datasheet for Ab348619 to confirm which applications have been experimentally validated, recommended dilutions, and compatible secondary antibodies.

Experimental Protocol Guidance

While exact conditions should always be taken from the product-specific datasheet, the following general guidelines reflect best practices for antibodies targeting cell-surface TNF superfamily members such as CD70:

Flow Cytometry

1. Harvest cells and wash twice with cold PBS containing 1% BSA (FACS buffer).
2. Block non-specific binding with Fc receptor blocking reagent for 10 minutes on ice.
3. Incubate cells with the recommended dilution of CD70 Antibody (Ab348619) for 30 minutes at 4°C.
4. Wash twice with FACS buffer and incubate with an appropriate fluorochrome-conjugated secondary antibody if required.
5. Wash, resuspend in FACS buffer containing a viability dye, and acquire on a flow cytometer.

Immunohistochemistry (FFPE)

1. Deparaffinize sections and rehydrate through a graded ethanol series to water.
2. Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) as recommended on the datasheet.
3. Block endogenous peroxidase activity with 3% H₂O₂ for 10 minutes.
4. Block with serum or protein block for 30 minutes and apply CD70 primary antibody at the recommended dilution overnight at 4°C.
5. Apply HRP-conjugated secondary antibody, develop with DAB substrate, counterstain with hematoxylin, dehydrate, and mount.

Always include appropriate isotype control and positive/negative tissue controls in every experiment.

CD70 in Tumor Immunology and Therapeutic Research

CD70 has emerged as a high-priority target in immuno-oncology for several compelling reasons. Its restricted expression in normal tissues, combined with frequent overexpression in hematologic malignancies and select solid tumors, creates a favorable therapeutic window. Several research and clinical programs have explored anti-CD70 modalities including:

• Antibody-drug conjugates (ADCs): Leveraging anti-CD70 antibodies to deliver cytotoxic payloads selectively to CD70-expressing tumor cells.
• CAR-T cell therapy: Engineering chimeric antigen receptor T cells targeting CD70 for treatment of renal cell carcinoma and AML.
• Bispecific antibodies: Redirecting immune effector cells to CD70-positive tumors.

Research-grade CD70 antibodies such as Ab348619 are essential tools in these pipelines—used to confirm target expression in patient-derived samples, screen cell lines, and evaluate receptor density prior to therapeutic development. Accurate characterization of CD70 expression by validated immunological methods is a prerequisite for meaningful translational research.

Antibody Selection and Quality Considerations

Selecting the right CD70 antibody for a given application requires consideration of several parameters:

• Host species and isotype: Ensure compatibility with secondary detection reagents and multiplex panels.
• Clonality: Monoclonal antibodies offer high lot-to-lot consistency and defined epitope specificity, while polyclonal antibodies may provide stronger signal but with greater variability.
• Conjugation: Unconjugated antibodies offer flexibility; directly conjugated formats (e.g., PE, FITC, APC) simplify flow cytometry workflows.
• Validated applications: Always verify that the specific antibody has been tested in your intended application—do not assume cross-application utility without data.
• Reactivity: Confirm that the antibody detects CD70 in your species of interest (human, mouse, etc.).
• Lot-specific quality control data: Review QC documentation including SDS-PAGE purity, ELISA titer, and functional validation data provided with Ab348619.

For ordering, technical support, or additional documentation on CD70 Antibody (Ab348619), contact Aladdin Scientific directly or visit the product page on our website.

Frequently asked questions

What is CD70 and why is it an important research target?

CD70 (TNFSF7) is the ligand for the co-stimulatory receptor CD27 and a member of the TNF superfamily. It plays a central role in T-cell and NK-cell activation and immune memory formation. CD70 is an important research target because it is aberrantly overexpressed in multiple cancers—including renal cell carcinoma and lymphomas—while being largely absent from most normal tissues, making it attractive for both biomarker studies and therapeutic development.

Which experimental applications is the CD70 Antibody (Ab348619) suitable for?

CD70 antibodies are commonly used in flow cytometry, immunohistochemistry (IHC), immunofluorescence (IF), Western blot, and immunoprecipitation. Researchers should consult the official Ab348619 datasheet for the specific list of experimentally validated applications and recommended working dilutions, as confirmed applications may vary by lot.

How should I store the CD70 Antibody to maintain its activity?

Antibody storage conditions should always follow the instructions provided in the product datasheet for Ab348619. In general, antibodies are best stored at -20°C for long-term storage, and repeated freeze-thaw cycles should be avoided by aliquoting upon first use. Short-term storage at 4°C is typically acceptable for periods of up to one month.

What controls should I include when using CD70 Antibody in flow cytometry?

When performing flow cytometry with CD70 Antibody, include an isotype control antibody of the same host species, clonality, and conjugate to assess non-specific background staining. Additionally, use a known CD70-positive cell line or activated lymphocytes as a positive control, and include a viability dye to exclude dead cells from analysis.

Can CD70 Antibody (Ab348619) be used for therapeutic purposes?

No. Ab348619 is strictly a research-use-only (RUO) reagent and is not approved, validated, or intended for diagnostic or therapeutic applications in humans or animals. It is designed exclusively for in vitro laboratory research.

References

1. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature Reviews Immunology, 2003.
2. Lens SM, et al. The role of CD70 in T-cell activation and disease. Immunology Today, 1999.
3. Jacobs J, et al. CD70: an emerging target for cancer immunotherapy. Expert Opinion on Therapeutic Targets, 2015.
4. Aladdin Scientific. CD70 Antibody, catalog Ab348619. Product datasheet.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.